Use of plasma volume expanders in myocardial revascularisation
The optimal solution for priming cardiopulmonary bypass machines and for postoperative resuscitation following myocardial revascularisation should be inexpensive, free of risk of transmitting disease, and free of other detrimental side effects. Colloid solutions are preferred over crystalloid solutions because of elevations in extracellular sodium and water that occur with cardiopulmonary bypass. Albumin, plasma protein solution, hetastarch (hydroxyethyl starch) and dextran are available for use if blood is not necessary and mediastinal blood is not available. Hetastarch is associated with a lower risk of bleeding and less risk of allergic reaction than dextran, and its cost is substantially less than that of albumin. However, high doses increase the risk of bleeding complications.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1992 |
|---|---|
| Erschienen: |
1992 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Drugs - 44(1992), 5 vom: 15. Nov., Seite 720-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lacy, J H [VerfasserIn] |
|---|
| Themen: |
Colloids |
|---|
| Anmerkungen: |
Date Completed 31.12.1992 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM012607622 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM012607622 | ||
| 003 | DE-627 | ||
| 005 | 20231221053048.0 | ||
| 007 | tu | ||
| 008 | 231221s1992 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0042.xml |
| 035 | |a (DE-627)NLM012607622 | ||
| 035 | |a (NLM)1280564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lacy, J H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of plasma volume expanders in myocardial revascularisation |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.1992 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The optimal solution for priming cardiopulmonary bypass machines and for postoperative resuscitation following myocardial revascularisation should be inexpensive, free of risk of transmitting disease, and free of other detrimental side effects. Colloid solutions are preferred over crystalloid solutions because of elevations in extracellular sodium and water that occur with cardiopulmonary bypass. Albumin, plasma protein solution, hetastarch (hydroxyethyl starch) and dextran are available for use if blood is not necessary and mediastinal blood is not available. Hetastarch is associated with a lower risk of bleeding and less risk of allergic reaction than dextran, and its cost is substantially less than that of albumin. However, high doses increase the risk of bleeding complications | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Colloids |2 NLM | |
| 650 | 7 | |a Dextrans |2 NLM | |
| 650 | 7 | |a Hydroxyethyl Starch Derivatives |2 NLM | |
| 650 | 7 | |a Plasma Substitutes |2 NLM | |
| 700 | 1 | |a Wright, C B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d 1976 |g 44(1992), 5 vom: 15. Nov., Seite 720-7 |w (DE-627)NLM00001611X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:1992 |g number:5 |g day:15 |g month:11 |g pages:720-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 1992 |e 5 |b 15 |c 11 |h 720-7 | ||